FAM118B

Last update 08 May 2025

Basic Info

Synonyms

FAM118B, family with sequence similarity 118 member B, FLJ21103

+ [1]

Introduction

May play a role in Cajal bodies formation.

100 Clinical Results associated with FAM118B

100 Translational Medicine associated with FAM118B

0 Patents (Medical) associated with FAM118B

Literatures (Medical) associated with FAM118B

01 Apr 2025·Journal of Neuropathology & Experimental Neurology

Low-grade glial/glioneuronal tumor with YAP1::FAM118B fusion: A novel molecular finding

Article

Author: El-Dana, Fouad ; Sheth, Sameer Anil ; Mandel, Jacob ; Lu, Hsiang-Chih ; Aldape, Kenneth ; Abdullaev, Zied

01 Sep 2023·Neurology India

C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B Fusion Negative Anaplastic Ependymoma with Lipogenic Differentiation

Author: Sharma, Mehar Chand ; Sable, Mukund Namdev ; Pattnaik, Ashis ; Purkait, Suvendu ; Jha, Shilpy ; Mulgulwar, Prit Benny

Lipogenic differentiation in ependymoma is an infrequent occurrence with very few reported cases. The grading was done solely based on the histomorphology and molecular subtyping was not described in such ependymomas. New molecular classification divided ependymomas in nine different subgroups, of which supratentorial location tumor usually exhibits C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B fusion proteins. A 46-year-old female presented with headache and right-sided parapresis. Radilogy revealed a large intraxial left parietooccipital mass lesion, which histologically and immuohistochemically confirmed as anaplastic ependymoma with extensive lipogenic changes. The ependymal origin of the tumor was corroborated by the immunohistochemistry and ultrastructural studies. Molecular studies for C11orf95-RELA, YAP1-MAMLD1, and YAP1-FAM118B fusion proteins were negative. This is the first documentation of fusion negative supratentorial anaplastic ependymoma with lipogenic differentiation. This novel finding needs further reinforcement by similar studies to identify its impact on the disease outcome.

23 Apr 2023·Russian Journal of Archive of Pathology

Verification of the diagnosis of supratentorial ependymomas by real-time PCR

Article

Author: Petrova, E.I. ; Kushel, Y.V. ; Ryzhova, M.V. ; Shaikhaev, E.G. ; Lavrinovich, A.O. ; Galstyan, S.A. ; Gorelyshev, S.K. ; Snigireva, G.P. ; Kumirova, E.V. ; Zheludkova, O.G. ; Telysheva, E.N.

Background. Differential diagnosis of supratentorial ependymomas is of particular difficulty in neurooncology due to nonspecific clinical and radiographic findings, a rare seen «classic» morphological picture, and a nonspecific immunophenotype. Thanks to molecular genetic methods, in particular real-time PCR, it has become possible to verify supratentorial ependymomas and identify their molecular group, on which further prognosis depends. Objective. To develop a set of molecular genetic tests based on real-time PCR to verify supratentorial ependymomas. Material and methods. 56 tissue samples were collected from patients with supratentorial ependymomas, WHO Grade II, and anaplastic ependymomas, WHO Grade III. We developed primers and fluorescent TaqMan probes for real-time PCR analysis to detect the ZFTA::RELA, ZFTA::MAML2, ZFTA::NCOA2, ZFTA::MAML3, YAP1::MAMLD1, and YAP1::FAM118B gene fusions. For immunohistochemical analysis, monoclonal rabbit anti-NF-kb p65 antibodies (HUABIO, China) were used, the study was carried out on AutostainerLink 48 immunostainer (DAKO, Denmark). Results. Real-time PCR was able to verify the diagnosis for 69.9% (n=39) of samples and classify them into molecular groups of ZFTA- or YAP1-positive supratentorial ependymomas. Immunohistochemically it was possible to verify 58% (n=29) ependymomas. Conclusion. Diagnosis by real-time PCR is a relatively fast, accessible and easily interpreted method that allows verification of the molecular group in 70% of cases of supratentorial ependymomas without the use of additional methods.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

FAM118B

Basic Info

Related

Analysis